Vigamox: profile and news

Moxifloxacin Concentrations Higher Than Gatifloxacin in Eye ... May 4, 2006
FT. LAUDERDALE, FL -- May 4, 2006 -- Higher antimicrobial activity and concentration of moxifloxacin (Vigamox) when compared to gatifloxacin (Zymar) may help ... - DG News

(BW) Alcon's First Quarter Sales Rise 8.1 Percent, Net Earnings ... Apr 24, 2006
Sales of infection/inflammation products rose 8.4 percent led by increased penetration of Vigamox(R) ophthalmic solution in the US and the contribution to ... - Houston Chronicle,

Other information

Indication
For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Acinetobacter lwoffii* Micrococcus luteus* Haemophilus influenzae Staphylococcus aureus Haemophilus parainfluenzae* Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Chlamydia trachomatis Staphylococcus warneri* Streptococcus pneumoniae

Pharmacology
Moxifloxacin is a quinolone/fluoroquinolone antibiotic. Moxifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Moxifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

Mechanism Of Action
The bactericidal action of Moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.

Drug Category
Anti-bacterial Agents; Quinolones; ATC:J01MA14

Brand Names/Synonyms
Avelox; Avelox I.V.; CHEMBANK1636; Moxifloxacin; Moxifloxacin Hcl; Moxifloxacin Hydrochloride; Vigamox

Dosage Forms
SOLUTION; TABLET

Absorption
Not Available

Interactions
-->Interactions for Moxifloxacin:

Drug-drug interaction studies have not been conducted with VIGAMOX™ solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2 indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.

Chemical IUPAC Name
1-cyclopropyl-7-(5,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1H-quinoline-3-carboxylicacid

Chemical Formula
C21H24FN3O4

Half Life
13 hours

Drug Type
Approved Drug

# Accession No
APRD00281

CAS Registry Number
151096-09-2